{"id":"rapamycin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute infectious disease","Ascites","BK Polyomavirus Reactivation Nephropathy","Body fluid retention","Breastfeeding (mother)","Bronchial Anastomotic Dehiscence in Lung Transplant","Cerebrovascular accident","Cytomegalovirus infection","Diabetes mellitus","Disease of liver","Gastrointestinal perforation","Hepatic Artery Thrombosis in Liver Transplant","Hyperbilirubinemia","Hypercholesterolemia","Hyperglycemia","Hyperlipidemia","Hypertensive disorder","Hypertriglyceridemia","Impaired wound healing","Infectious disease","Interstitial lung disease","Interstitial pneumonia","Kidney disease","Lymphedema","Malignant lymphoma","Malignant neoplasm of brain","Malignant neoplasm of skin","Pericardial effusion","Perioperative care","Peripheral edema","Pleural Effusions","Pneumocystosis jiroveci pneumonia","Pregnancy, function","Primary malignant neoplasm","Progressive multifocal leukoencephalopathy","Proteinuria","Secondary malignant neoplasm of cerebrum","Sirolimus Toxicity","Surgical procedure","Transplant of lung","Transplantation of liver"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Sirolimus","Rapamune","X-Rapamune","Rapacan","Siromus"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2"},"_scrapedAt":"2026-03-28T00:04:00.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Gorham's disease","diseaseId":"gorham's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lymphangiectasis","diseaseId":"lymphangiectasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lymphangioma","diseaseId":"lymphangioma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lymphangiomatosis","diseaseId":"lymphangiomatosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Kidney Transplant Rejection","diseaseId":"prevention-of-kidney-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary lymphangioleiomyomatosis","diseaseId":"pulmonary-lymphangioleiomyomatosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Renal cell carcinoma","diseaseId":"renal-cell-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tuberous sclerosis syndrome","diseaseId":"tuberous-sclerosis-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06653842","phase":"PHASE2","title":"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-12-20","conditions":"Cutaneous Venous Malformations","enrollment":15},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT06239480","phase":"PHASE3","title":"SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-07-31","conditions":"Microcystic Lymphatic Malformation","enrollment":51},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT01396408","phase":"PHASE2","title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2012-02-09","conditions":"Advanced Rare Tumours","enrollment":137},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03047213","phase":"PHASE2","title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-24","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma","enrollment":17},{"nctId":"NCT01375829","phase":"PHASE1","title":"Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-27","conditions":"Adult Solid Neoplasm","enrollment":22},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT04141020","phase":"PHASE2","title":"Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms","status":"RECRUITING","sponsor":"University of Miami","startDate":"2021-10-27","conditions":"Cerebral Aneurysm","enrollment":80},{"nctId":"NCT02215720","phase":"PHASE1","title":"Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-04-26","conditions":"Patients With Advanced or Metastatic Solid Tumors","enrollment":45},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT03950609","phase":"PHASE2","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-30","conditions":"Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1","enrollment":36},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT06950385","phase":"PHASE3","title":"Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis","status":"RECRUITING","sponsor":"Rapamycin Holdings Inc.","startDate":"2025-07-18","conditions":"Familial Adenomatous Polyposis (FAP)","enrollment":168},{"nctId":"NCT04485559","phase":"PHASE1","title":"Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-12-09","conditions":"Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma","enrollment":50},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT07329088","phase":"NA","title":"Isoleucine Addition Treatment Effects in a Controlled Diet Study","status":"NOT_YET_RECRUITING","sponsor":"Jean L. Fry","startDate":"2026-05-04","conditions":"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight","enrollment":40},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT06437574","phase":"PHASE2","title":"Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2024-07-16","conditions":"Prostate Cancer","enrollment":140},{"nctId":"NCT05810870","phase":"PHASE2","title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-05-24","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":14},{"nctId":"NCT02389309","phase":"PHASE1","title":"Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-10-05","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":14},{"nctId":"NCT07443826","phase":"PHASE1, PHASE2","title":"CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy","status":"RECRUITING","sponsor":"Unlimited Biotechnology LLC","startDate":"2026-03-31","conditions":"Age-related Muscle Decline","enrollment":12},{"nctId":"NCT05012371","phase":"PHASE2","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-16","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":90},{"nctId":"NCT05342519","phase":"PHASE2","title":"Daily Topical Rapamycin for Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-07-28","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT07144150","phase":"NA","title":"EVERO Drug-coated Balloon (DCB) Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Cook Research Incorporated","startDate":"2026-02","conditions":"Peripheral Vascular Disease, Peripheral Arterial Disease","enrollment":410},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT03933904","phase":"PHASE2","title":"Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2019-09-25","conditions":"Castleman Disease, Castleman's Disease, Multicentric","enrollment":7},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT02574728","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2015-06","conditions":"Cancer","enrollment":46},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT07436611","phase":"PHASE2","title":"Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains","status":"NOT_YET_RECRUITING","sponsor":"AFT Pharmaceuticals, Ltd.","startDate":"2026-04","conditions":"Port Wine Stains","enrollment":30},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT03304678","phase":"PHASE2","title":"Discovery of Sirolimus Sensitive Biomarkers in Blood","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-12-04","conditions":"Lymphangioleiomyomatosis","enrollment":33},{"nctId":"NCT07054320","phase":"","title":"Rapamycin and Infection-related Illness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoskinson Health and Wellness Clinic","startDate":"2025-08-06","conditions":"Infectious Diseases","enrollment":15},{"nctId":"NCT03065062","phase":"PHASE1","title":"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors","status":"SUSPENDED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-02-28","conditions":"Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer","enrollment":75},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT02397083","phase":"PHASE2","title":"Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","enrollment":102},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT03008408","phase":"PHASE2","title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-18","conditions":"Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma","enrollment":90},{"nctId":"NCT05949658","phase":"PHASE1","title":"Rapalog Pharmacology (RAP PAC) Study","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-05-15","conditions":"Aging","enrollment":72},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":"Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma","enrollment":1376},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT06727305","phase":"PHASE1, PHASE2","title":"MTOR Inhibitors in Older Adults","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Aging","enrollment":60},{"nctId":"NCT07378657","phase":"PHASE3","title":"Systematic Approach for Children With Orbital Malformation With Sirolimus Use","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-01","conditions":"Orbital Lymphatic Malformation","enrollment":30},{"nctId":"NCT07359807","phase":"PHASE2, PHASE3","title":"A Prospective, Randomized, Multi-center Trial Comparing the MagicTouch PTA Sirolimus-coated Balloon to Paclitaxel-coated Balloons for the Treatment of Stenotic or Occluded Femoropopliteal Arteries in Peripheral Arterial Disease (PAD) Patients.","status":"NOT_YET_RECRUITING","sponsor":"Concept Medical Inc.","startDate":"2026-04","conditions":"Popliteal Artery Disease, Superficial Femoral Artery Disease","enrollment":478},{"nctId":"NCT07354620","phase":"EARLY_PHASE1","title":"A Pilot Study on Reverse Aging (The REVERSE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Christ Hospital","startDate":"2025-02-15","conditions":"Aging","enrollment":52},{"nctId":"NCT05467397","phase":"PHASE1, PHASE2","title":"Feasibility of [11C]Acetate-PET in LAM and TSC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-30","conditions":"Lymphangioleiomyomatosis, Tuberous Sclerosis Complex","enrollment":7},{"nctId":"NCT07352852","phase":"","title":"Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-05-14","conditions":"Intracranial Arterial Stenosis, Brain Diseases","enrollment":300},{"nctId":"NCT01087554","phase":"PHASE1","title":"Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-03","conditions":"Advanced Cancer","enrollment":249},{"nctId":"NCT02979873","phase":"PHASE2","title":"Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-12-19","conditions":"Severe Aplastic Anemia","enrollment":84},{"nctId":"NCT04789070","phase":"PHASE3","title":"Phase III Trial of Sirolimus in IBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-07-01","conditions":"Inclusion Body Myositis","enrollment":140},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03065387","phase":"PHASE1","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-31","conditions":"Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation","enrollment":93},{"nctId":"NCT06528301","phase":"PHASE1","title":"A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies","status":"RECRUITING","sponsor":"Umoja Biopharma","startDate":"2025-03-10","conditions":"Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL)","enrollment":106},{"nctId":"NCT06310291","phase":"EARLY_PHASE1","title":"VTP-1000 in Adults With Celiac Disease","status":"RECRUITING","sponsor":"Barinthus Biotherapeutics","startDate":"2024-08-01","conditions":"Celiac Disease","enrollment":45},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT00975819","phase":"PHASE2","title":"Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies","status":"COMPLETED","sponsor":"Denise Martin Adams","startDate":"2009-10","conditions":"Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation","enrollment":61},{"nctId":"NCT05384756","phase":"PHASE1","title":"TMLI and Alemtuzumab for Treatment of Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-13","conditions":"Sickle Cell Disease","enrollment":2},{"nctId":"NCT04542733","phase":"NA","title":"The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2021-02-10","conditions":"Kidney Transplant Infection, BK Virus Infection","enrollment":50},{"nctId":"NCT04172922","phase":"PHASE1","title":"Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions","status":"TERMINATED","sponsor":"Nemours Children's Clinic","startDate":"2020-04-01","conditions":"Vascular Anomaly","enrollment":5},{"nctId":"NCT05836025","phase":"PHASE2","title":"Effect of Rapamycin in Ovarian Aging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2023-06-01","conditions":"Perimenopausal","enrollment":50},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT07302932","phase":"NA","title":"Metformin and Molecular Aging in Prediabetes","status":"COMPLETED","sponsor":"Diabetes Foundation, India","startDate":"2023-02-01","conditions":"Metformin, Prediabetes","enrollment":112},{"nctId":"NCT05105152","phase":"PHASE1","title":"PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-11-29","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT02509468","phase":"PHASE2","title":"suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2015-09-30","conditions":"Vascular Malformation","enrollment":63},{"nctId":"NCT01282697","phase":"PHASE1","title":"Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2011-04-22","conditions":"Refractory Solid Tumors in Children","enrollment":42},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT03243019","phase":"PHASE2","title":"Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2018-06-25","conditions":"Lymphatic Malformation, Pediatric","enrollment":28},{"nctId":"NCT04948203","phase":"PHASE2, PHASE3","title":"Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2021-07-09","conditions":"Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID","enrollment":60},{"nctId":"NCT04177004","phase":"PHASE1","title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-04-30","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":53},{"nctId":"NCT05835999","phase":"PHASE2","title":"Everolimus Aging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-24","conditions":"Aging, Insulin Resistance","enrollment":106},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT01869114","phase":"PHASE2","title":"Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-07-08","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":57},{"nctId":"NCT03363763","phase":"PHASE2","title":"Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex","status":"TERMINATED","sponsor":"Aucta Pharmaceuticals, Inc","startDate":"2017-04-12","conditions":"Angiofibroma of Face, Tuberous Sclerosis","enrollment":24},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT01885689","phase":"PHASE2","title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-02-10","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission","enrollment":72},{"nctId":"NCT05661461","phase":"PHASE1","title":"Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","status":"RECRUITING","sponsor":"Aadi Bioscience, Inc.","startDate":"2022-11-23","conditions":"Tumor, Solid, Tumor, Advanced Solid Tumor","enrollment":28},{"nctId":"NCT00600496","phase":"PHASE1","title":"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2007-12-14","conditions":"Breast Cancer, Breast Neoplasms, Colon Cancer","enrollment":140},{"nctId":"NCT02321501","phase":"PHASE1","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":37},{"nctId":"NCT00776373","phase":"PHASE1, PHASE2","title":"Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2007-01","conditions":"ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00977574","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma","enrollment":349},{"nctId":"NCT01187199","phase":"PHASE1","title":"Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08-19","conditions":"Advanced Cancer","enrollment":278},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT01582191","phase":"PHASE1","title":"Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05-14","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":42312,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Rapamycin","genericName":"Rapamycin","companyName":"Institut National de la Santé Et de la Recherche Médicale, France","companyId":"institut-national-de-la-sant-et-de-la-recherche-m-dicale-france","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":72,"withResults":11},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}